DFG
RNAC icon

Delphi Financial Group’s Cartesian Therapeutics RNAC Stock Holding History

Delphi Financial Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,028
Closed -$229K – 28
2025
Q2 		$229K Hold
22,028
– – 0.16% 22
2025
Q1 		$290K Hold
22,028
– – 0.18% 22
2024
Q4 		$395K Hold
22,028
– – 0.21% 22
2024
Q3 		$355K Hold
22,028
– – 0.2% 20
2024
Q2 		$595K Hold
22,028
– – 0.33% 23
2024
Q1 		$430K Hold
22,028
– – 0.28% 23
2023
Q4 		$456K Hold
22,028
– – 0.27% 19
2023
Q3 		$701K Hold
22,028
– – 0.34% 17
2023
Q2 		$740K Hold
22,028
– – 0.38% 25
2023
Q1 		$919K Hold
22,028
– – 0.45% 24
2022
Q4 		$747K Buy
+22,028
New +$937K 0.38% 25

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Delphi Financial Group's RNAC Position: Q3 2025 in Review

Delphi Financial Group sold out of Cartesian Therapeutics (RNAC) in Q3 2025, closing a stake of 22,028 shares — an estimated $229K sold.

Delphi Financial Group first reported a position in RNAC in Q4 2022 and held it in 11 quarters. The position peaked at $919K in Q1 2023. 68 funds tracked by Wall St. Rank hold RNAC as of Q3 2025.

  • Delphi Financial Group reported no remaining Cartesian Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Delphi Financial Group sold 22,028 Cartesian Therapeutics shares in Q3 2025, an estimated $229K.
  • Delphi Financial Group first reported a position in Cartesian Therapeutics in Q4 2022 and held it in 11 quarters.
  • Delphi Financial Group's Cartesian Therapeutics position peaked at $919K in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2025.

Based on Delphi Financial Group's 13F filing for Q3 2025, filed 14 Nov 2025.